Survival and low-grade glioma: The emergence of genetic information

Elizabeth B. Claus, Kyle M. Walsh, John K. Wiencke, Annette M. Molinaro, Joseph L. Wiemels, Joellen M. Schildkraut, Melissa L. Bondy, Mitchel Berger, Robert Brian Jenkins, Margaret Wrensch

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Significant gaps exist in our understanding of the causes and clinical management of glioma. One of the biggest gaps is how best to manage low-grade (World Health Organization [WHO] Grade II) glioma. Low-grade glioma (LGG) is a uniformly fatal disease of young adults (mean age 41 years), with survival averaging approximately 7 years. Although LGG patients have better survival than patients with high-grade (WHO Grade III or IV) glioma, all LGGs eventually progress to high-grade glioma and death. Data from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute suggest that for the majority of LGG patients, overall survival has not significantly improved over the past 3 decades, highlighting the need for intensified study of this tumor. Recently published research suggests that historically used clinical variables are not sufficient (and are likely inferior) prognostic and predictive indicators relative to information provided by recently discovered tumor markers (e.g., 1p/19q deletion and IDH1 or IDH2 mutation status), tumor expression profiles (e.g., the proneural profile) and/or constitutive genotype (e.g., rs55705857 on 8q24.21). Discovery of such tumor and constitutive variation may identify variables needed to improve randomization in clinical trials as well as identify patients more sensitive to current treatments and targets for improved treatment in the future. This article reports on survival trends for patients diagnosed with LGG within the United States from 1973 through 2011 and reviews the emerging role of tumor and constitutive genetics in refining risk stratification, defining targeted therapy, and improving survival for this group of relatively young patients.

Original languageEnglish (US)
Article numberE6
JournalNeurosurgical Focus
Volume38
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Glioma
Survival
Neoplasms
SEER Program
National Cancer Institute (U.S.)
Tumor Biomarkers
Random Allocation
Young Adult
Therapeutics
Genotype
Clinical Trials
Mutation
Research

Keywords

  • Epidemiology
  • Genes
  • Glioma
  • GWAS
  • Low grade
  • SEER
  • Survival
  • Treatment

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Claus, E. B., Walsh, K. M., Wiencke, J. K., Molinaro, A. M., Wiemels, J. L., Schildkraut, J. M., ... Wrensch, M. (2015). Survival and low-grade glioma: The emergence of genetic information. Neurosurgical Focus, 38(1), [E6]. https://doi.org/10.3171/2014.10.FOCUS12367

Survival and low-grade glioma : The emergence of genetic information. / Claus, Elizabeth B.; Walsh, Kyle M.; Wiencke, John K.; Molinaro, Annette M.; Wiemels, Joseph L.; Schildkraut, Joellen M.; Bondy, Melissa L.; Berger, Mitchel; Jenkins, Robert Brian; Wrensch, Margaret.

In: Neurosurgical Focus, Vol. 38, No. 1, E6, 2015.

Research output: Contribution to journalArticle

Claus, EB, Walsh, KM, Wiencke, JK, Molinaro, AM, Wiemels, JL, Schildkraut, JM, Bondy, ML, Berger, M, Jenkins, RB & Wrensch, M 2015, 'Survival and low-grade glioma: The emergence of genetic information', Neurosurgical Focus, vol. 38, no. 1, E6. https://doi.org/10.3171/2014.10.FOCUS12367
Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM et al. Survival and low-grade glioma: The emergence of genetic information. Neurosurgical Focus. 2015;38(1). E6. https://doi.org/10.3171/2014.10.FOCUS12367
Claus, Elizabeth B. ; Walsh, Kyle M. ; Wiencke, John K. ; Molinaro, Annette M. ; Wiemels, Joseph L. ; Schildkraut, Joellen M. ; Bondy, Melissa L. ; Berger, Mitchel ; Jenkins, Robert Brian ; Wrensch, Margaret. / Survival and low-grade glioma : The emergence of genetic information. In: Neurosurgical Focus. 2015 ; Vol. 38, No. 1.
@article{e27f5cd09ce64f859ae7a2b128c75c63,
title = "Survival and low-grade glioma: The emergence of genetic information",
abstract = "Significant gaps exist in our understanding of the causes and clinical management of glioma. One of the biggest gaps is how best to manage low-grade (World Health Organization [WHO] Grade II) glioma. Low-grade glioma (LGG) is a uniformly fatal disease of young adults (mean age 41 years), with survival averaging approximately 7 years. Although LGG patients have better survival than patients with high-grade (WHO Grade III or IV) glioma, all LGGs eventually progress to high-grade glioma and death. Data from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute suggest that for the majority of LGG patients, overall survival has not significantly improved over the past 3 decades, highlighting the need for intensified study of this tumor. Recently published research suggests that historically used clinical variables are not sufficient (and are likely inferior) prognostic and predictive indicators relative to information provided by recently discovered tumor markers (e.g., 1p/19q deletion and IDH1 or IDH2 mutation status), tumor expression profiles (e.g., the proneural profile) and/or constitutive genotype (e.g., rs55705857 on 8q24.21). Discovery of such tumor and constitutive variation may identify variables needed to improve randomization in clinical trials as well as identify patients more sensitive to current treatments and targets for improved treatment in the future. This article reports on survival trends for patients diagnosed with LGG within the United States from 1973 through 2011 and reviews the emerging role of tumor and constitutive genetics in refining risk stratification, defining targeted therapy, and improving survival for this group of relatively young patients.",
keywords = "Epidemiology, Genes, Glioma, GWAS, Low grade, SEER, Survival, Treatment",
author = "Claus, {Elizabeth B.} and Walsh, {Kyle M.} and Wiencke, {John K.} and Molinaro, {Annette M.} and Wiemels, {Joseph L.} and Schildkraut, {Joellen M.} and Bondy, {Melissa L.} and Mitchel Berger and Jenkins, {Robert Brian} and Margaret Wrensch",
year = "2015",
doi = "10.3171/2014.10.FOCUS12367",
language = "English (US)",
volume = "38",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

TY - JOUR

T1 - Survival and low-grade glioma

T2 - The emergence of genetic information

AU - Claus, Elizabeth B.

AU - Walsh, Kyle M.

AU - Wiencke, John K.

AU - Molinaro, Annette M.

AU - Wiemels, Joseph L.

AU - Schildkraut, Joellen M.

AU - Bondy, Melissa L.

AU - Berger, Mitchel

AU - Jenkins, Robert Brian

AU - Wrensch, Margaret

PY - 2015

Y1 - 2015

N2 - Significant gaps exist in our understanding of the causes and clinical management of glioma. One of the biggest gaps is how best to manage low-grade (World Health Organization [WHO] Grade II) glioma. Low-grade glioma (LGG) is a uniformly fatal disease of young adults (mean age 41 years), with survival averaging approximately 7 years. Although LGG patients have better survival than patients with high-grade (WHO Grade III or IV) glioma, all LGGs eventually progress to high-grade glioma and death. Data from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute suggest that for the majority of LGG patients, overall survival has not significantly improved over the past 3 decades, highlighting the need for intensified study of this tumor. Recently published research suggests that historically used clinical variables are not sufficient (and are likely inferior) prognostic and predictive indicators relative to information provided by recently discovered tumor markers (e.g., 1p/19q deletion and IDH1 or IDH2 mutation status), tumor expression profiles (e.g., the proneural profile) and/or constitutive genotype (e.g., rs55705857 on 8q24.21). Discovery of such tumor and constitutive variation may identify variables needed to improve randomization in clinical trials as well as identify patients more sensitive to current treatments and targets for improved treatment in the future. This article reports on survival trends for patients diagnosed with LGG within the United States from 1973 through 2011 and reviews the emerging role of tumor and constitutive genetics in refining risk stratification, defining targeted therapy, and improving survival for this group of relatively young patients.

AB - Significant gaps exist in our understanding of the causes and clinical management of glioma. One of the biggest gaps is how best to manage low-grade (World Health Organization [WHO] Grade II) glioma. Low-grade glioma (LGG) is a uniformly fatal disease of young adults (mean age 41 years), with survival averaging approximately 7 years. Although LGG patients have better survival than patients with high-grade (WHO Grade III or IV) glioma, all LGGs eventually progress to high-grade glioma and death. Data from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute suggest that for the majority of LGG patients, overall survival has not significantly improved over the past 3 decades, highlighting the need for intensified study of this tumor. Recently published research suggests that historically used clinical variables are not sufficient (and are likely inferior) prognostic and predictive indicators relative to information provided by recently discovered tumor markers (e.g., 1p/19q deletion and IDH1 or IDH2 mutation status), tumor expression profiles (e.g., the proneural profile) and/or constitutive genotype (e.g., rs55705857 on 8q24.21). Discovery of such tumor and constitutive variation may identify variables needed to improve randomization in clinical trials as well as identify patients more sensitive to current treatments and targets for improved treatment in the future. This article reports on survival trends for patients diagnosed with LGG within the United States from 1973 through 2011 and reviews the emerging role of tumor and constitutive genetics in refining risk stratification, defining targeted therapy, and improving survival for this group of relatively young patients.

KW - Epidemiology

KW - Genes

KW - Glioma

KW - GWAS

KW - Low grade

KW - SEER

KW - Survival

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84942501073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942501073&partnerID=8YFLogxK

U2 - 10.3171/2014.10.FOCUS12367

DO - 10.3171/2014.10.FOCUS12367

M3 - Article

C2 - 25552286

AN - SCOPUS:84942501073

VL - 38

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 1

M1 - E6

ER -